Viewing Study NCT03630159

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:24 PM
Ignite Modification Date: 2026-02-21 @ 6:07 PM
Study NCT ID: NCT03630159
Status: COMPLETED
Last Update Posted: 2022-08-15
First Post: 2018-08-01
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Large B-cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lymphoma tisagenlecleucel View
None Diffuse Large B-cell Lymphoma View
None CTL019 View
None PORTIA View
None DLBCL View
None tisagenlecleucel View
None pembrolizumab View
None r/r Diffuse large B-cell Lymphoma View
None relapsed/refractory Diffuse large B-cell Lymphoma View